ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Nkarta Inc

Nkarta Inc (NKTX)

10.81
-0.275
(-2.48%)
Closed March 29 04:00PM
11.29
0.48
(4.44%)
After Hours: 07:50PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
11.29
Bid
11.02
Ask
11.30
Volume
1,197,044
10.59 Day's Range 11.37
1.28 52 Week Range 16.24
Market Cap
Previous Close
11.085
Open
10.80
Last Trade Time
Financial Volume
$ 13,014,503
VWAP
10.8722
Average Volume (3m)
2,159,367
Shares Outstanding
49,072,342
Dividend Yield
-
PE Ratio
-4.66
Earnings Per Share (EPS)
-2.32
Revenue
-
Net Profit
-113.84M

About Nkarta Inc

Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and d... Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. It is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The company's operations are based in South San Francisco, California and it operates in one segment. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Nkarta Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NKTX. The last closing price for Nkarta was $11.09. Over the last year, Nkarta shares have traded in a share price range of $ 1.28 to $ 16.24.

Nkarta currently has 49,072,342 shares outstanding. The market capitalization of Nkarta is $529.98 million. Nkarta has a price to earnings ratio (PE ratio) of -4.66.

NKTX Latest News

Nkarta Announces Pricing of $240 Million Underwritten Offering

SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced...

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

First patient dosing on track for first half of 2024 in clinical trial of NKX019 in lupus nephritis using disease-tailored lymphodepletionAdditional B-cell mediated autoimmune diseases under...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">144: Remarks and SignatureRemarksThe securities to be sold were acquired upon the exercise of stock options and the vesting of restricted stock...

Nkarta to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">144: Remarks and SignatureRemarksDate of Notice02/12/2024Date of Plan Adoption or Giving of Instruction, If Relying on Rule...

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.9-14.404852160713.1913.98.47270871310.24454513CS
40.010.088652482269511.2816.248.47125589411.63679366CS
125.66100.532859685.6316.245.5215936710.38103062CS
269.65588.4146341461.6416.241.2824540376.04875375CS
527.81224.4252873563.4816.241.2814384485.60242247CS
156-23.29-67.351069982634.5840.641.2896656410.88843137CS
260-43.46-79.378995433854.7579.161.2882094212.52985905CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

NKTX Discussion

View Posts
jondoeuk jondoeuk 7 days ago
Brutal https://www.oncologypipeline.com/apexonco/another-false-dawn-nkarta
πŸ‘οΈ0
jondoeuk jondoeuk 2 weeks ago
AACR abstracts

3603 / 9 - NKX101, an allogeneic off-the-shelf CAR NK cell therapy targeting NKG2D-Ls, has potent anti-leukemic activity alone or in combination with Ara-C https://www.abstractsonline.com/pp8/#!/20272/presentation/7138

3604 / 10 - NKX101, an allogeneic off-the-shelf NKG2D CAR-NK cell therapy, has potent in vitro cytotoxicity against patient-derived AML leukemic stem cells and non-leukemic stem cell blasts https://www.abstractsonline.com/pp8/#!/20272/presentation/7139
πŸ‘οΈ0
jondoeuk jondoeuk 2 weeks ago
AFMD has been hit with the CEO going, and CMO acting as the interim, both the CSO and CFO resigning, and R/S. Let's hope the data is positive as times remain tough in the NK field. If so, investors should probably expect a cash raise.

As for NKTX, hope they start selecting optimal donors and testing ML NKs, especially for solid tumours https://aacrjournals.org/clincancerres/article/27/17/4859/671641/Memory-like-Differentiation-Enhances-NK-Cell https://aacrjournals.org/cancerres/article/83/7_Supplement/893/719928/Abstract-893-Memory-like-differentiation-enhances
πŸ‘οΈ0
Monksdream Monksdream 3 weeks ago
NKTX new 52 week high
πŸ‘οΈ0
Monksdream Monksdream 4 weeks ago
NKTX new 52 week high
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
NKTX new 52 week high
πŸ‘οΈ0
LowFloatLopes LowFloatLopes 3 months ago
I’m at $7.10 just sold half at 10 in less than 20 minutes
πŸ‘οΈ0
LowFloatLopes LowFloatLopes 3 months ago
Wowsers am I the only one here
πŸ‘οΈ0
NY1972 NY1972 3 months ago
MF SZ CTCL must be the best friend for bios. TRIL, AFMD, ... all had good response with their CD47, CD30 ..
πŸ‘οΈ0
jondoeuk jondoeuk 3 months ago
πŸ‘οΈ0
Mt. Blanc Mt. Blanc 5 months ago
There it goes as expected. NKTX selling off.
πŸ‘οΈ0
Triple nickle Triple nickle 5 months ago
Yuppers trust the Nickle
πŸ‘οΈ0
LowFloatLopes LowFloatLopes 5 months ago
Thanks for heads up this is going nuts lol
πŸ‘οΈ0
Triple nickle Triple nickle 5 months ago
Boom
πŸ‘οΈ0
INV4 INV4 5 months ago
Nkarta's Stock Climbs 28% After FDA Approves Drug Application

Nkarta's shares rallied after the company said its investigational new drug application for NKX019, a treatment for lupus nephritis, was approved by the U.S. Food and Drug Administration.

The stock climbed 28% to $1.89 in late morning trading Tuesday. The stock hit a 52-week low of $1.28 earlier this month, and the shares are down 69% this year.

The company said its multi-center, open label, dose escalation clinical trial will assess the safety and clinical activity of NKX019 in patients with refractory lupus nephritis.

Nkarta, a biopharmaceutical company based in South San Francisco, Calif., said it is a developer of engineered natural killer cell therapies.

Lupus nephritis is a form of systemic lupus erythematosus, and is developed by about 40% of the estimated 200,000 people in the U.S. diagnosed with the disease. Of that group, 30% will develop end stage kidney disease, which can be fatal unless they receive dialysis or a kidney transplant.

https://ih.advfn.com/stock-market/NASDAQ/nkarta-NKTX/stock-news/92295683/nkartas-stock-climbs-28-after-fda-approves-drug-a

$NKTX
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
NKTA under $2
πŸ‘οΈ0
jondoeuk jondoeuk 7 months ago
Updated
πŸ‘οΈ0
NY1972 NY1972 9 months ago
With all the edits, CAR NK is more like ADC, not NK cells that have also been described as β€˜immune-regulatory’ because of their ability to produce an array of cytokines and chemokines, through which they help shape B cell and T cell responses, and impact the function of DC, macrophages and neutrophils
πŸ‘οΈ0
jondoeuk jondoeuk 9 months ago
More from $NKTX hopes to avoid the fate of $FATE, via @evaluatevantage -> https://t.co/1SOK7gOAbS— Jacob Plieth (@JacobPlieth) June 27, 2023
πŸ‘οΈ0
jondoeuk jondoeuk 9 months ago
PR https://finance.yahoo.com/news/nkarta-updates-clinical-progress-car-110100481.html

Slides https://ir.nkartatx.com/static-files/681c0391-4a87-453b-91a5-2af3e6d3f477
πŸ‘οΈ0
jondoeuk jondoeuk 9 months ago
The update will be today at 8:00 a.m. ET https://nkx101-clinical-update-conference-call.open-exchange.net/registration
πŸ‘οΈ0
jondoeuk jondoeuk 10 months ago
PR https://www.globenewswire.com/news-release/2023/04/17/2648511/0/en/Nkarta-Presents-Preclinical-Data-Exploring-Gene-Knockout-Strategies-and-Combination-Agents-with-NK-Cell-Based-Therapies-at-the-2023-AACR-Annual-Meeting.html

Posters https://www.nkartatx.com/file.cfm/75/docs/nkarta_aacr2023_poster%20890_adam17%20ko%20of%20nk%20cells.pdf https://www.nkartatx.com/file.cfm/75/docs/nkarta_aacr2023_poster%203183_nkx101%20and%20cetuximab%20combo.pdf
πŸ‘οΈ0
jondoeuk jondoeuk 10 months ago
Yes, it could have been primary resistance due to low MICA/B (or other NKG2DLs) expression, but without any translational data from the company there is no way of knowing.
πŸ‘οΈ0
NY1972 NY1972 10 months ago
Disfunctional NKs have a few more mutations than dysfunctional NKs.
πŸ‘οΈ0
NY1972 NY1972 10 months ago
My point was MDS patients has disfunctional NK cells which cause the cancer to slow down on MICA expression. With lowered MICA expression, NKTX cells don't work. I doubt MDS TME is more suppressive than AML.
πŸ‘οΈ0
jondoeuk jondoeuk 10 months ago
In patient's there is immune cell dysfunction, but using off-the-shelf should be able to overcome some of that. As for primary, adaptive and/or acquired resistance, only translational data will be able to give insights as to what strategies could combat that.
πŸ‘οΈ0
jondoeuk jondoeuk 10 months ago
Yes, just a shame about the target.
πŸ‘οΈ0
NY1972 NY1972 10 months ago
It will be interesting to see how this DT HER2 x NKG2D x CD16A engager works since it won't be impacted by the # of ligands on cancer cells.
πŸ‘οΈ0
NY1972 NY1972 10 months ago
Cancer is adapting. Why bother expressing ligands if the NK cells are not working anyway.

NKG2D surface down-modulation in freshly isolated NK cells from MDS patients may be a clinically useful β€œbiomarker” of suppressed NK function.
πŸ‘οΈ0
jondoeuk jondoeuk 10 months ago
Without any translational data it is hard to say why. I know in one paper the authors reported that just 30% of MDS blasts expressed the NKG2D ligands MICA/B https://ashpublications.org/blood/article/109/11/4816/23111/Reduced-natural-killer-NK-function-associated-with

That was confirmed by another group, showing a low expression of NKG2D ligands https://www.nature.com/articles/leu2010149

There are plenty of other mechanisms, including Tregs, either via cell-to-cell interactions of soluble factors, such as TGF-B https://rupress.org/jem/article-lookup/doi/10.1084/jem.20051511
πŸ‘οΈ0
NY1972 NY1972 10 months ago
This one is puzzling. Four patients with MDS were treated, with no response observed.
πŸ‘οΈ0
jondoeuk jondoeuk 11 months ago
The update is expected to include longer-term follow up from patients who were in response as of the previous April '22 data cut-off; clinical data from at least ten new R/R AML patients treated at 1.5B (x3); clinical data from patients who received one or more additional three-dose cycles; and clinical data from a new cohort of patients who received lymphodepletion with cytarabine and fludarabine.
πŸ‘οΈ0
jondoeuk jondoeuk 11 months ago
Speaking of expansion. From this: ''We apply a human B-lymphoblastoid cell-line 721.221 (hereinafter, 221)-based artificial feeder cell system with membrane-bound interleukin 21 (mIL 21) to propagate NK and CAR-NK cells. The expansion capability, purity, and cytotoxicity of NK cells expanded with 221-mIL-21 feeder cells are superior to that of conventional K562-mIL-21 feeder cells. RNA sequencing (RNA-seq) data show that 221-mIL-21 feeder cell-expanded NK cells display a less differentiated, non-exhausted, limited fratricidal, memory-like phenotype correlated with enriched metabolic pathways, which explains underlying mechanisms.'' https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(20)30138-8

Also, additional ways that could improve it https://ashpublications.org/blood/article/118/21/4035/68863/Nicotinamide-a-Form-of-Vitamin-B3-Promotes https://aacrjournals.org/cancerres/article/77/20/5664/623001/GSK3-Inhibition-Drives-Maturation-of-NK-Cells-and https://www.cell.com/cell-metabolism/fulltext/S1550-4131(21)00130-3
πŸ‘οΈ0
jondoeuk jondoeuk 11 months ago
Some more info. Pre-activation is IL-12/15/18 and expansion with uAPCs (engineered K562 feeder cells expressing mbIL-21 and 4-1BBL) plus IL-2, transduction with a retroviral vector, before another round of expansion. From two cord blood units, 250 doses have been manufactured with a (CAR) transduction efficiency of 60%. Six dose levels will be tested, with DL1 completed. Also, over 90 cryopreservation protocols were tested, with MDACC outperforming standard frozen.
πŸ‘οΈ0
jondoeuk jondoeuk 11 months ago
Turns out the trial in solid tumours (ccRCC, mesothelioma, or osteosarcoma) is open. However, there are a number of differences, including design of the CAR (which has constitutive IL-15), ex vivo expansion, and they are using CB-derived NKs.
πŸ‘οΈ0
jondoeuk jondoeuk 11 months ago
(OT) Dr. Rezvani presented some early, but impressive data showing activity with an CD70-targeted CAR-NK cell therapy in a patient with R/R cHL, from a basket trial for R/R haematological malignancies. A trial in solid tumours should be starting soon.

πŸ‘οΈ0
jondoeuk jondoeuk 12 months ago
Updated results from the ongoing trial of NKX101 should be presented this quarter.
πŸ‘οΈ0
jondoeuk jondoeuk 1 year ago
ADAM17 knockout NK or CAR NK cells augment antibody dependent cellular cytotoxicity (ADCC) and anti-tumor activity https://www.abstractsonline.com/pp8/#!/10828/presentation/3022

Combination of anti-EGFR antibody cetuximab with NKX101, an allogeneic NKG2D-L targeting NK cell therapy, enhances potency and in vitro cytotoxicity against solid tumors https://www.abstractsonline.com/pp8/#!/10828/presentation/3049
πŸ‘οΈ0
jondoeuk jondoeuk 1 year ago
Watching from the sidelines, but the NKX101 delayed data readout is a worry.
πŸ‘οΈ0
jondoeuk jondoeuk 1 year ago
NKX019 update https://www.globenewswire.com/news-release/2022/12/05/2567250/0/en/Nkarta-Announces-Updated-Clinical-Data-on-Anti-CD19-Allogeneic-CAR-NK-Cell-Therapy-NKX019-for-Patients-with-Relapsed-or-Refractory-Non-Hodgkin-Lymphoma.html

Slides https://ir.nkartatx.com/static-files/9cb11d46-a4aa-49a3-baca-dc1a36e5aa60

Webcast https://nkarta-nkx019-clinical-update-conference-call.open-exchange.net/registration
πŸ‘οΈ0
jondoeuk jondoeuk 1 year ago
Posters

https://www.nkartatx.com/file.cfm/75/docs/nkarta_sitc_2022_poster_381_nk_cell_expansion.pdf

https://www.nkartatx.com/file.cfm/75/docs/nkarta_sitc_2022_poster_902_nkx019_cd20_mab_combo.pdf
πŸ‘οΈ0
jondoeuk jondoeuk 1 year ago
SITC titles

Large-scale expansion and engineering of human NK cells sourced from peripheral blood versus umbilical cord blood

NKX019, an Off-the-Shelf CD19 CAR-NK Cell, mediates improved anti-tumor activity and persistence in combination with CD20-directed therapeutic mAbs
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
Additional NKX101 and NKX019 clinical data expected by year-end. The data is expected to include safety and activity data for newly enrolled patients at higher dose monotherapy regimen and extended durability follow-up for previously reported patient responses. Also, in June, the company filed a protocol amendment with the FDA for 019 to optimise the trial's design as they prepare for potential dose expansion cohorts. The amended protocol, now in effect, allows for an increased dose of cyclophosphamide with lymphodepletion, in line with 101, and various expansion cohorts evaluating it in combination with rituximab.
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
Cowen 3rd Annual Oncology Innovation Summit webcast https://wsw.com/webcast/cowen115/nktx/2047935
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
Time for some momo/fomo to kick in. Let's go NKTX!
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
Offering is now closed Company raised over $200M within a few sessions. Let's see if tutes accumulate NKTX shares today. Possibly 20.00+ today!
πŸ‘οΈ0
stock1ace1 stock1ace1 2 years ago
20$
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
NKTX is a great $$$$$ opportunity.
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
Not a p&d. Some folks need to learn how to read a corporate balance sheet / and SEC filings.
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
18.93 > > Looks like NKTX shelf placement is completed. Looks like another $200M in the kitty.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock